Cancer Statistics 2026: Now published👇
Cancer mortality has fallen 34% since 1991 (4.8M deaths averted). 5-year survival is now 70%! Metastatic disease improved from 17% to 35%.
Lung cancer remains the leading killer‼️
https://t.co/69LeIEPMwm
The Paclitaxel + Carboplatin "CarboTaxol" doublet is the bread and butter of oncology for a reason. 🍞🧈
But why does this specific combo work so well?
It’s all about the "Freeze and Snap" synergy. ❄️💥
1️⃣ The Freezer (Paclitaxel):
Paclitaxel stabilizes microtubules, preventing depolymerization.
It freezes the cell’s skeleton in the M-phase (Mitosis). The cell tries to divide but gets stuck. 🛑
2️⃣ The Snap (Carboplatin):
While the cell is arrested and stressed, Carboplatin slides in.
It acts as an alkylating agent, forming reactive platinum complexes that bind to DNA (cross-linking). 🧬🔗
🤝 The Synergy (Why 1+1 = 3):
The magic lies in the timing.
Paclitaxel arrests cells in the G2/M phase.
Cells in this phase are less efficient at repairing the DNA damage caused by Carboplatin.
The "Freeze" prevents the "Repair," leading to accumulation of DNA damage ➡️ Apoptosis (Cell Death). ☠️
💡 Clinical Pearl (The Sequence Matters):
This is why we often administer Taxane before Platinum.
Giving Paclitaxel first avoids the antagonistic effect where Carboplatin might inhibit the uptake or cytotoxicity of the taxane.
It also reduces thrombocytopenia! 📉🩸
#Oncology #MedTwitter #OncTwitter
@OncoAlert@myesmo@esmo_open@asco
🆕article in press: association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study @angela_toss@matteolambe
https://t.co/QNmTMXo9Fr